Agenus Inc. (AGEN, Financial) recently experienced a notable decline in its stock price, dropping by 5.12% to $2.88 per share with a trading volume of 476,673 shares and a turnover rate of 2.21%. The stock's volatility was measured at 7.26%. Recent financial reports revealed that Agenus generated a revenue of $25.11 million with a net loss of $66.39 million, resulting in an earnings per share (EPS) of -$3.08. The company's gross profit stood at $21.62 million, and its price-to-earnings (P/E) ratio was -0.26.
Regarding investment advice, 20% of the five analysts covering the stock recommend a buy, while 80% suggest holding the stock, with no sell recommendations.
Within the biotechnology industry, where Agenus operates, the overall decline was 0.72%. Comparatively, Molecular Templates, Inc., Psyence Biomedical, and X4 Pharmaceuticals showed significant gains. Other active stocks in the sector include Molecular Templates, Inc., Elevai Labs, Inc., and Pulmatrix, Inc., with turnover rates of 3564.87%, 3199.09%, and 362.99%, respectively. Notable volatility was observed in Molecular Templates, Inc., Pulmatrix, Inc., and Psyence Biomedical.
Agenus Inc. is a clinical-stage company in the United States, developing therapies to activate the immune system to combat cancer and infections. Their product pipeline includes immune-modulating antibodies and cell therapies provided through their subsidiaries MiNK Therapeutics Inc. and SaponiQx Inc., which also offers vaccine adjuvants. Key antibody candidates from the company are botensilimab, an engineered CTLA-4 antibody known as AGEN1811, and balstilimab, a PD-1 antibody.
